Three pharmaceutical related agreements signed between China and the United States

[January 16, 2020 / medical information list] three drug related agreements signed between China and the United States; key business of BMS will be disclosed in the next two years; Yuming Ueno will be the new president of Mitsubishi pharmaceutical; the first pancreatic cancer mitigation data of "moon landing plan" will be disclosed On May 15, China and the United States signed the economic and trade agreement between the government of the people's Republic of China and the government of the United States of America, in which the three aspects of drugs, namely, "intellectual property rights", "extension of valid patent period" and "counterfeit drugs", deserve attention (Ministry of Finance) On June 16, Jingfeng pharmaceutical announced the revised notice of 2019 performance forecast According to the announcement, in 2019, Jingfeng pharmaceutical's net profit is expected to lose RMB 850-650 million, a decrease of 555.00% - 447.94% over the same period of last year (Jingfeng pharmaceutical notice) On the 16th, yaomingbio and Bayer jointly announced an agreement to take over the operation of Bayer's biological preparation plant in Leverkusen, Germany, purchase relevant equipment and a long-term lease contract attached to the plant (Yao Ming Biology) Giovanni caforio, chairman and CEO of BMS, said in this year's JPM that in the next two years, BMS plans to have eight important research breakthroughs, extending the indications of opdivo yevoy immunotherapy to the first-line treatment of NSCLC (CPHL Pharma online) Recently, the company announced that its 61 year old executive director, Yukio Ueno, would be promoted to the new president, effective April 1 Sanjin, the former president, is retiring as a director (medical representative) Recently, through its wholly-owned subsidiary universal cells, astralas has reached an agreement with adaptimmune to jointly develop and commercialize allogeneic T-cell therapy, which will bring new stem cell sources to cancer patients (knows medicine) On May 15, BMS announced that FDA has accepted a supplementary biological product license application submitted by it and granted priority review, and the prescription drug user fee method is May 15, 2020 The SBLA applied for the approval of opdivo and yervoy combination therapy for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK genomic tumor distortion (Biovalley) At the 38th JP Morgan conference, Dr Huang Xinxiang, with the clinical data of patients in the "moon landing program", showed that pd-l1.t-hank combined with n-803 therapy was completely relieved in a case of metastatic pancreatic cancer (medical and wheat guest) Clovis oncology recently announced that the FDA has accepted an application for a new drug supplement targeted at the anticancer drug rubraca and granted priority review The target date of its prescription drug user fee law is May 15, 2020 (Biovalley) Italian pharmaceutical company recordati recently announced that the European Commission has approved the marketing license of orphan drug product isturia ® (osilodostat), which is used to treat adult endogenous Cushing's syndrome (Biovalley) The second batch of Guocai will be opened on January 17 As of January 16, 2020, a total of 204 varieties (calculated by drug name) have passed / deemed to have passed the consistency evaluation, of which 49 varieties have passed the consistency evaluation, and the number of enterprises has exceeded 3 (Insight database)